CD8hi+CD57+ T lymphocytes are enriched in antigen-specific T cells capable of down-modulating cytotoxic activity

被引:75
作者
Mollet, L
Sadat-Sowti, B
Duntze, J
Leblond, V
Bergeron, F
Calvez, V
Katlama, C
Debré, P
Autran, B
机构
[1] CHU Pitie Salpetriere, Lab Immunol Cellulaire & Tissulaire, CNRS URA 625, F-75013 Paris, France
[2] Hop La Pitie Salpetriere, Dept Hematol, F-75651 Paris 13, France
[3] Hop La Pitie Salpetriere, Virol Lab, F-75651 Paris 13, France
[4] Hop La Pitie Salpetriere, Dept Maladies Infect, F-75651 Paris 13, France
关键词
AIDS/HIV; CD8(+)CD57(+) lymphocytes; cytotoxic T lymphocytes; immunomodulators; transplantation;
D O I
10.1093/intimm/10.3.311
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Major expansions of CD8(hi+)CD57(+) T lymphocytes frequently occur during human immunodeficiency virus (HIV) infection and after transplantation. To investigate mechanisms of such cell expansion, we compared the activation and functional status of CD8(hi+)CD57(+) and CD57(-) peripheral blood lymphocytes (PBL) from normal, bone marrow transplantation (BMT) and HIV+ donors, The CD8(hi+)CD57(+) PBL from BMT and HIV+ donors preferentially displayed CD38 and HLA-DR activation markers without correlation between CD8(hi+)CD57(+) percentages and HIV load, the CD45RA(+) isoform in all ex vivo conditions but acquired CD45RO after in vitro expansion, CD11b and CD11c in BMT and HIV+ donors but decreased expression of CD62-L, VLA-2 and VLA-6, The CD8(hi+)CD57(+) cells were positive for perforin and granzyme B and spontaneously mediated cytolytic activity in a CD3-redirected assay, In contrast the inhibitor of cytolytic functions (ICF) produced by CD8(hi+)CD57(+) cells down-modulated the CD3-redirected cytolytic activity but only at low levels of CD3 cross-linking, While CD3-triggering induced a low, if any, short-term proliferation of CD8(+)CD57(+) cells, this subset could be amplified after long-term stimulation either with mitogens or with HIV antigens, thereby enriched in HIV-specific T cells producing tumor necrosis factor-alpha, Altogether these data suggest that CD8(hi+)CD57(+) cells represent a terminal differentiation state of activated effector cytotoxic T lymphocytes which are enriched in antigen-specific T cells and down-modulate their own cytolytic potential, thus participating in a negative control of effector cell functions during persistent viral infections or transplantations.
引用
收藏
页码:311 / 323
页数:13
相关论文
共 59 条
  • [21] HO HN, 1993, J IMMUNOL, V150, P3070
  • [22] INTEGRINS - VERSATILITY, MODULATION, AND SIGNALING IN CELL-ADHESION
    HYNES, RO
    [J]. CELL, 1992, 69 (01) : 11 - 25
  • [23] SERIAL KILLING BY CYTOTOXIC T-LYMPHOCYTES - T-CELL RECEPTOR TRIGGERS DEGRANULATION, RE-FILLING OF THE LYTIC GRANULES AND SECRETION OF LYTIC PROTEINS VIA A NON-GRANULE PATHWAY
    ISAAZ, S
    BAETZ, K
    OLSEN, K
    PODACK, E
    GRIFFITHS, GM
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (04) : 1071 - 1079
  • [24] HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1-SPECIFIC CYTOTOXIC T-LYMPHOCYTES RELEASE GAMMA-INTERFERON, TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA), AND TNF-BETA WHEN THEY ENCOUNTER THEIR TARGET ANTIGENS
    JASSOY, C
    HARRER, T
    ROSENTHAL, T
    NAVIA, BA
    WORTH, J
    JOHNSON, RP
    WALKER, BD
    [J]. JOURNAL OF VIROLOGY, 1993, 67 (05) : 2844 - 2852
  • [25] JOLY P, 1989, J IMMUNOL, V143, P2193
  • [26] The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses
    Kagi, D
    Seiler, P
    Pavlovic, J
    Ledermann, B
    Burki, K
    Zinkernagel, RM
    Hengartner, H
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (12) : 3256 - 3262
  • [27] FAS AND PERFORIN PATHWAYS AS MAJOR MECHANISMS OF T-CELL-MEDIATED CYTOTOXICITY
    KAGI, D
    VIGNAUX, F
    LEDERMANN, B
    BURKI, K
    DEPRAETERE, V
    NAGATA, S
    HENGARTNER, H
    GOLSTEIN, P
    [J]. SCIENCE, 1994, 265 (5171) : 528 - 530
  • [28] Selectins and their ligands: Current concepts and controversies
    Kansas, GS
    [J]. BLOOD, 1996, 88 (09) : 3259 - 3287
  • [29] LANDAY A, 1983, J IMMUNOL, V131, P2757
  • [30] LANIER LL, 1984, J IMMUNOL, V132, P151